Neurologische Klinik und Poliklinik
Refine
Has Fulltext
- yes (524)
Year of publication
Document Type
- Journal article (356)
- Doctoral Thesis (165)
- Report (2)
- Book (1)
Keywords
- ischemic stroke (27)
- multiple sclerosis (22)
- Parkinson's disease (19)
- deep brain stimulation (19)
- Parkinson’s disease (18)
- neuroinflammation (18)
- Fabry disease (17)
- Multiple Sklerose (17)
- stroke (17)
- Schlaganfall (16)
- neuropathic pain (15)
- Polyneuropathie (14)
- inflammation (13)
- Medizin (12)
- Parkinson-Krankheit (12)
- pain (12)
- Neuropathie (10)
- subthalamic nucleus (10)
- neuropathy (9)
- Schmerz (8)
- biomarker (8)
- dopamine (8)
- dystonia (8)
- neurology (8)
- Charcot-Marie-Tooth (7)
- cytokines (7)
- macrophages (7)
- mouse model (7)
- neurodegeneration (7)
- skin biopsy (7)
- small fiber neuropathy (7)
- B cells (6)
- Fabry-Krankheit (6)
- Hautbiopsie (6)
- MS (6)
- Makrophage (6)
- Maus (6)
- Neurodegeneration (6)
- Neuropathischer Schmerz (6)
- Pain (6)
- Parkinson (6)
- acute ischemic stroke (6)
- antibodies (6)
- autoantibodies (6)
- depression (6)
- fibromyalgia syndrome (6)
- Autoantikörper (5)
- B7-H1 (5)
- Biomarker (5)
- Dystonie (5)
- EAE (5)
- Entzündung (5)
- Fibromyalgie (5)
- Immunsystem (5)
- MRI (5)
- Makrophagen (5)
- Neurofascin (5)
- Parkinson disease (5)
- Ranvier-Schnürring (5)
- basal ganglia (5)
- blood-brain barrier (5)
- gene expression (5)
- magnetic resonance imaging (5)
- middle cerebral artery occlusion (5)
- movement disorders (5)
- neuroprotection (5)
- polyneuropathy (5)
- skin punch biopsy (5)
- traumatic brain injury (5)
- tremor (5)
- walking (5)
- ALS (4)
- CCI (4)
- Charcot-Marie-Syndrom (4)
- Cytokines (4)
- GFAP (4)
- Myelin (4)
- Nervenfaser (4)
- Neuroinflammation (4)
- Neuronale Plastizität (4)
- Neuropathy (4)
- Propriozeption (4)
- Puppenhandillusion (4)
- T-Lymphozyt (4)
- blood–brain barrier (4)
- cervical dystonia (4)
- corneal confocal microscopy (4)
- disease (4)
- factor XII (4)
- fibromyalgia (4)
- gait initiation (4)
- immunohistochemistry (4)
- inflammasome (4)
- macrophage (4)
- mechanical thrombectomy (4)
- mice (4)
- microRNA (4)
- motor learning (4)
- mutation (4)
- myelin (4)
- platelets (4)
- regulatory T cells (4)
- thrombo-inflammation (4)
- Autoantibodies (3)
- Biopsie (3)
- Blut-Hirn-Schranke (3)
- CMT (3)
- COVID-19 (3)
- Carotisstenose (3)
- Caspr (3)
- Chemokine (3)
- DYT1 (3)
- ELISPOT (3)
- Entmarkung (3)
- Fabry (3)
- Fabry-associated pain (3)
- Gehirn (3)
- Genexpression (3)
- Guillain-Barré-Syndrom (3)
- HBMEC (3)
- Inflammation (3)
- Langerhans cells (3)
- Macrophage (3)
- Mausmodell (3)
- Mice (3)
- Multiple sclerosis (3)
- NLRP3 (3)
- Natalizumab (3)
- Nervendegeneration (3)
- Neuralgie (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- PNP (3)
- Peripheres Nervensystem (3)
- Rehabilitation (3)
- Synuclein <alpha-> (3)
- T cells (3)
- T-lymphocytes (3)
- Ultraschalldiagnostik (3)
- Ureaplasma parvum (3)
- Zytokine (3)
- adaptive immune system (3)
- aging (3)
- animal models (3)
- anxiety (3)
- autoantibody (3)
- biomarkers (3)
- brain (3)
- cerebellar tDCS (3)
- cerebral ischemia (3)
- children (3)
- chronic pain (3)
- closed head injury (3)
- cognitive impairment (3)
- complement (3)
- criteria (3)
- degeneration (3)
- dementia (3)
- enzyme replacement therapy (3)
- essential tremor (3)
- experimental autoimmune encephalomyelitis (3)
- experimental stroke (3)
- expression (3)
- gait analysis (3)
- genetics (3)
- heart failure (3)
- immune cells (3)
- immune system (3)
- kinematics (3)
- length of stenosis (3)
- local field potentials (3)
- lymphocytes (3)
- meningitis (3)
- mesencephalic locomotor region (3)
- miRNA (3)
- microglia (3)
- neurofascin (3)
- neurofilament light chain (3)
- neuroimmunology (3)
- neuropathischer Schmerz (3)
- neutrophils (3)
- photothrombotic stroke (3)
- quality of life (3)
- rehabilitation (3)
- rubber hand illusion (3)
- stroke unit (3)
- tMCAO (3)
- therapy (3)
- thrombolysis (3)
- tight junctions (3)
- transcranial magnetic stimulation (3)
- transplantation (3)
- trial (3)
- AQP4 (2)
- Acetylcholinrezeptor (2)
- Altern (2)
- Alzheimer’s disease (2)
- Antikörper (2)
- Arteria carotis interna (2)
- B-lymphocytes (2)
- BDNF (2)
- Basalganglien (2)
- CIDP (2)
- CNS (2)
- CSF-1 (2)
- Cerebrospinal fluid (2)
- Charcot-Marie-Tooth disease (2)
- Cortactin (2)
- Crush (2)
- Cytokine (2)
- Degeneration (2)
- Diabetes mellitus (2)
- Diagnosis (2)
- Dystonia (2)
- Elektrophysiologie (2)
- Encephalopathia hepatica (2)
- Enzyme replacement therapy (2)
- Evoziertes Potenzial (2)
- Fabry genotype (2)
- Fabry phenotype (2)
- Fc-receptor (2)
- Fibromyalgia (2)
- Fibromyalgia syndrome (2)
- Glatiramer acetate (2)
- Guillain-Barre-Syndrome (2)
- Guillain-Barré syndrome (2)
- HLA-G (2)
- Haut (2)
- Hautstanzbiopsie (2)
- IENFD (2)
- Ischemic stroke (2)
- Komplement (2)
- Körperselbstgefühl (2)
- Körperwahrnehmung (2)
- LTD (2)
- Langzeitdepression (2)
- Lewy-like pathology (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- MBP (2)
- MCC950 (2)
- MCP-1 (2)
- Mechanisms (2)
- Meningitis (2)
- Microglia (2)
- Morbus Fabry (2)
- Motorisches Lernen (2)
- Multiple Sclerosis (2)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (2)
- NEUROWIND (2)
- NMOSD (2)
- NMR-Tomographie (2)
- NOAC (2)
- Nervenbiopsie (2)
- Neuroimmunologie (2)
- Neuronal ceroid lipofuscinosis (2)
- Nucleus subthalamicus (2)
- Outcome survey (2)
- PET (2)
- Peripheral nervous system (2)
- Proprioception (2)
- Quantitative sensorische Testung (2)
- Schwann cell (2)
- Schwann-Zelle (2)
- Serotonin (2)
- Small fiber Neuropathie (2)
- Small fiber neuropathy (2)
- Spinalganglion (2)
- Stroke (2)
- Stroke unit (2)
- T lymphocytes (2)
- T-Lymphozyten (2)
- TDMT (2)
- Tiermodell (2)
- Tourette syndrome (2)
- Transkranielle magnetische Stimulation (2)
- Treatment (2)
- TrkB (2)
- Ultraschall (2)
- Ureaplasma urealyticum (2)
- Zentralnervensystem (2)
- accuracy (2)
- alpha-synuclein (2)
- amyotrophic-lateral-sclerosis (2)
- animal model (2)
- anticoagulation (2)
- atrial fibrillation (2)
- autoimmune (2)
- autoimmunity (2)
- axonal damage (2)
- axonaler Schaden (2)
- balance (2)
- base of support (2)
- beta oscillations (2)
- binding (2)
- biopsy (2)
- blood brain barrier (2)
- blood flow (2)
- blood pressure (2)
- blood-brain-barrier (2)
- c-Fos (2)
- caregiver burden (2)
- carotid atherosclerosis (2)
- carotid stenosis (2)
- carotid ultrasound (2)
- case report (2)
- central nervous system (2)
- cerebral autoregulation (2)
- cerebrospinal fluid (2)
- cerebrovascular disorders (2)
- chemokines (2)
- chronic cerebrovascular disease (2)
- chronic kidney disease (2)
- colony-stimulating factor (2)
- consolidation (2)
- contact-kinin system (2)
- contactin (2)
- cytokine (2)
- degree of stenosis (2)
- demyelination (2)
- diabetic neuropathy (2)
- diagnosis (2)
- diagnostic markers (2)
- differential diagnosis (2)
- dimethyl fumarate (2)
- disability (2)
- diseases of the nervous system (2)
- echocardiography (2)
- edema (2)
- electrophysiology (2)
- endoglin (2)
- endothelial cells (2)
- exercise (2)
- freezing of gait (2)
- gait (2)
- gene (2)
- generalized cerebral edema (2)
- glial fate modulation (2)
- glial fibrillary acidic protein (2)
- globotriaosylceramide (2)
- glycine receptor (2)
- glycoprotein receptor Ib (2)
- guidelines (2)
- hearing loss (2)
- hypoxia (2)
- immunomodulation (2)
- in vivo imaging (2)
- induced pluripotent stem cells (2)
- infarction (2)
- inflammatory neuropathy (2)
- ion channels (2)
- ischemic penumbra (2)
- just noticeable difference (JND) (2)
- lesions (2)
- leukocytes (2)
- locomotor adaptation (2)
- locus coeruleus (2)
- machine learning (2)
- major depression (2)
- miR-21 (2)
- miRNS (2)
- mitochondria (2)
- mortality (2)
- motor control (2)
- mouse models (2)
- multiple system atrophy (2)
- multiple-sclerosis (2)
- musical syntax (2)
- nerve biopsy (2)
- nerve fibers (2)
- nerve fibres (2)
- neurological disorders (2)
- neuronal plasticity (2)
- neurons (2)
- neuroscience (2)
- node of Ranvier (2)
- opioids (2)
- outcomes (2)
- pain questionnaire (2)
- pain-related evoked potentials (2)
- parkinson's disease (2)
- passive transfer (2)
- pathogenesis (2)
- peripheral blood mononuclear cells (2)
- peripheral nervous system (2)
- peripheral neuropathy (2)
- photothrombosis (2)
- physical activity (2)
- preclinical research (2)
- predictive value (2)
- prognosis (2)
- protein (2)
- psychophysics (2)
- quantitative sensory testing (2)
- randomized controlled trial (2)
- rat (2)
- relapse (2)
- renal system (2)
- resting tremor (2)
- reversible posterior leukoencephalopathy syndrome (2)
- second hit (2)
- small fiber pathology (2)
- spinal cord (2)
- spinal cord injury (2)
- split-belt treadmill (2)
- striatum (2)
- stroke care (2)
- synaptic vesicles (2)
- systems biology (2)
- tDCS (2)
- telemedicine (2)
- thrombosis (2)
- time perception (2)
- transient ischemic attack (2)
- transient middle cerebral artery occlusion (2)
- ultrasound (2)
- velocity (2)
- voluntary movement (2)
- von Willebrand factor (2)
- α-synuclein (2)
- (Para-)nodale Autoantikörper (1)
- 2B (1)
- 3D fluoroscopy (1)
- 3D structure (1)
- 3D-Struktur (1)
- 5-Dihydroxycinnamat (1)
- 5-HIAA (1)
- 5-HTT Knock Out (1)
- 5-dihydroxycinnamate (1)
- 5IA-SPECT (1)
- 65-kda isoform (1)
- A delta-Faser (1)
- A-delta fibers (1)
- A53T (1)
- A53T mutation (1)
- A53T-Mutation (1)
- ACE (1)
- ADHD (1)
- ALS mimic (1)
- ALS treatment (1)
- ALSIN gene (1)
- APERIO (1)
- APERIO Hybrid (1)
- AQP (1)
- ASC (1)
- ASIC 3 (1)
- ATF3 (1)
- Abciximab (1)
- Adaptive cell transfer (1)
- Adaptives Immunsystem (1)
- Adaptorproteine (1)
- Adult patients (1)
- Affekt (1)
- Agalsidase beta (1)
- Agalsidase beta therapy (1)
- Agaphelin (1)
- Age (1)
- Agrin (1)
- Alemtuzumab (1)
- Alkoholische Polyneuropathie (1)
- Allodynie (1)
- Alpha galactosidase (1)
- Alpha-Synuclein (1)
- Alter (1)
- Alzheimer disease (1)
- Alzheimer’s dementia (1)
- Amitriptylin (1)
- Amplitude (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anderson-Fabry Disease (1)
- Aneurysma (1)
- Animal models (1)
- Anosognosie (1)
- Anti-Neurofascin-Autoantikörper-assoziierten Neuropathie (1)
- Antibody index (1)
- Antigen CD8 (1)
- Antikoagulation (1)
- Antiparanodal Autoantibodies (1)
- Anxiety (1)
- Apoptosis (1)
- Approved immunomodulators (1)
- Aquaporin 4 (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Aquaporin4 (1)
- Arteria cerebri media (1)
- Arterial Diameters (1)
- Arterial water (1)
- Asomatognosie (1)
- Ataxia (1)
- Atrial fibrillation (1)
- Atrophie (1)
- Autoantigen (1)
- Autoimmun (1)
- Autoimmunität (1)
- Autophagie (1)
- Autophagie <Physiologie> (1)
- Axon (1)
- Axon degeneration (1)
- Axonal degeneration (1)
- Azathioprine (1)
- Aδ- and C-fibers (1)
- B-Lymphocyten (1)
- BB/OKL rats (1)
- BCI (1)
- Barkhof criteria (1)
- Barthel Index (1)
- Barthel-Index modified Rankin-Scale (1)
- Barthel-Index modifizierte Rankin-Skala (1)
- Basal Ganglia (1)
- Basal ganglia (1)
- Beam-Walking-Test (1)
- Beta-glucocerebrosidase (1)
- Bewegungsstörung (1)
- Bildgebung (1)
- Biopsiediagnostik von entzündlichen Polyneuropathien (1)
- Blutgerinnungsfaktor XII (1)
- Borrelien (1)
- Borreliose (1)
- Borreliosis (1)
- Braak (1)
- Brain (1)
- Brain atrophy (1)
- Brain edema (1)
- Brain ischemia (1)
- Brain-derived neurotrophic factor (1)
- Brainstem encephalitis (1)
- C-Faser (1)
- C-reactive protein (1)
- C.376A>G (p.S126G) (1)
- C1-inhibitor (1)
- C57BL/6 mice (1)
- CAS (1)
- CCL2 (1)
- CCS (1)
- CD105 (1)
- CD133 (1)
- CD19 (1)
- CD52 (1)
- CEA (1)
- CLN3 (1)
- CMV (1)
- CNS Myelination (1)
- CNS disease (1)
- CNS imaging (1)
- CNS integrity (1)
- COMPLEX 1 (1)
- COU254 (1)
- CRM (1)
- CRPS (1)
- CSF (1)
- CSF-1 Rezeptor (1)
- CSF-1 Rezeptor Inhibitor (1)
- CSF-1 receptor (1)
- CSF-1 receptor inhibitor (1)
- CSF-1-Rezeptor-Inhibitor (1)
- CSVD (1)
- CXCL10 (1)
- CXCL4 (1)
- CXCL5 (1)
- CXCL7 (1)
- CXCL8 (1)
- CXCR2 (1)
- Ca2+ homeostasis (1)
- Ca2+ ion analysis (1)
- Ca2+ leak (1)
- Ca2+ oscillation (1)
- Campylobacter jejuni (1)
- Capsaicin (1)
- Capsaicin receptor (1)
- Carotis (1)
- Carotischirurgie (1)
- Caspase (1)
- Caspr1 (1)
- Cell Index (1)
- Cell therapy (1)
- Cell-based assays (1)
- Central Nervous System (1)
- Cerebellitis (1)
- Cerebral blood flow (1)
- Cerebral small vessel disease (1)
- Cerebral vasospasm (1)
- Cerebral-ischemia (1)
- Cgrin (1)
- Charcot-Marie-Tooth Neuropathie (1)
- Charcot-Marie-Tooth Neuropathy (1)
- Charcot-Marie-Tooth syndrom (1)
- Charcot-Marie-Tooth-Hoffmann-Syndrom (1)
- Charcot–Marie–Tooth disease (1)
- Charcot–Marie–Tooth disease type 1A (1)
- Chemokine Receptor (1)
- Chemokinrezeptors (1)
- CholinomiRs (1)
- Chronic Constriction Injury (1)
- Chronic heart failure (1)
- Chronic neuropathic pain (1)
- Chronische Niereninsuffizienz (1)
- Chronischer Schmerz (1)
- Cisterna magna (1)
- Clinical manifestations (1)
- Clinically silent stroke (1)
- Coefficient (1)
- Cognitive behavior (1)
- Cognitive decline (1)
- Cold (1)
- Computertomographie (1)
- Connexin32 deficient mice (1)
- Connexin32-defiziente Maus (1)
- Consortium to Establish a Registry for Alzheimer's Disease (1)
- Contactin (1)
- Contactin 1 (1)
- Corneal confocal microscopy (1)
- Corneale confocale Mikroskopie (1)
- Cortico-striatal projection neurons (1)
- Crespi effect (1)
- Cyclophosphamid (1)
- Cyclophosphamide (1)
- D313Y genotype (1)
- DARPA (1)
- DBS biomarkers (1)
- DBS programming (1)
- DOPA-responsive-dystonia (1)
- DRD1 (1)
- DYT-TOR1A (1)
- Deep Brain Stimulation (1)
- Deeskalation (1)
- Deeskalationstherapie (1)
- Deflazacort (1)
- Dekompressionskraniektomie (1)
- Delphi procedure (1)
- Demenz (1)
- Demyelinating peripheral neuropathy (1)
- Demyelination (1)
- Demyelinisierung (1)
- Dendritische Zelle (1)
- Denervierung (1)
- Devic Maus (1)
- Devic mice (1)
- Devic’s syndrome (1)
- Diabetic polyneuropathy (1)
- Diabetische Neuropathie (1)
- Diabetische Polyneuropathie (1)
- Dialyse (1)
- Diapedese (1)
- Dimethylfumarat (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Disease (1)
- Donor lymphocytes (1)
- Dopamine (1)
- Dorsal Root Ganglion (1)
- Dorsal root ganglion (1)
- Dose reduction (1)
- Double hemorrhage model (1)
- Drosophila (1)
- Duchenne dystrphy (1)
- Durchblutung (1)
- Dyskinesie (1)
- EAAT2 (1)
- ECM (1)
- EEG (1)
- EEG data (1)
- EMG (1)
- ER Ca2+ imaging (1)
- ER Ca2+ store (1)
- ERK1/2 (1)
- ERT (1)
- ET (1)
- Edema (1)
- Effekte von Contactin-1-IgG-Patientenantikörpern im Zellkulturmodell (1)
- El Escorial (1)
- Electrophysiology (1)
- Embryonalentwicklung (1)
- Emotionales Verhalten (1)
- Encephalitis (1)
- Endarteriektomie (1)
- Endothelzelle (1)
- English version (1)
- Entzündungsreaktion (1)
- Entzündungsschmerz (1)
- Enzephalitis (1)
- Epilepsy (1)
- Epitop (1)
- Erbliche Neuropathien (1)
- Ereigniskorreliertes Potenzial (1)
- Erregbarkeit (1)
- Escalation therapy (1)
- Eskalationstherapie (1)
- Essentieller Tremor (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Evoked potentials (1)
- Evozierte Potenziale (1)
- Experimental stroke (1)
- Experimentaltumor (1)
- Experimenteller Schlaganfall (1)
- Expression (1)
- F-18-FDG PET (1)
- FOSMN (1)
- FOXP3 (1)
- FP-CIT SPECT (1)
- FSHD (1)
- FTY720 (1)
- FTY720-P (1)
- FXII (1)
- FXIIa inhibitor rHA-Infestin (1)
- Fabry cardiomyopathy (1)
- Fabry nephropathy (1)
- Fabry pain (1)
- Fabry’s disease (1)
- Facial nerve palsy (1)
- Facioscapulohumeral muscular dystrophy (1)
- Factor messenger-RNA (1)
- Fatigue (1)
- Fc-Rezeptor (1)
- Fibroblasten (1)
- Fibroblasts (1)
- Fluoreszenz (1)
- Fluoreszenzmikroskopie (1)
- Focal dystonie (1)
- Frabin/Fgd4 (1)
- Funktionelle Kernspintomografie (1)
- GABAergic neurons (1)
- GAP 43 (1)
- GCH1 (1)
- GFAP-astrocytopathies (1)
- GLA KO mouse model (1)
- GP-IIb/IIIa-Antagonist (1)
- GP-IIb/IIIa-antagonist (1)
- GPCR (1)
- GRAID (1)
- Gait initiation (1)
- Gedächtnis (1)
- Gefäßverschluss (1)
- Gehirn-Computer-Schnittstelle (1)
- Gene-expression (1)
- Genetik (1)
- Genmutation (1)
- Geriatrics (1)
- Geriatrie (1)
- Geste (1)
- Gland (1)
- Glial fibrillary acidic protein (1)
- Glioblastoma (1)
- Glioma stem cells (1)
- Glutamic-acid decarboxylase anxiety (1)
- Guillain-Barr'e-Syndrom (1)
- Guillain-Barré Syndrom (1)
- HMGB1 (1)
- HMSN (1)
- HMSN immune cells (1)
- HPF (1)
- HRUS (1)
- Hautzelle (1)
- Head-injury (1)
- Hearing loss (1)
- Heat Hyperalgesia (1)
- Hemodynamic depression (1)
- Heparin (1)
- Hepatische Enzephalopathie (1)
- Hereditary spastic paraplegia (1)
- Hereditäre Neuropathien (1)
- Hereditäre spastische Spinalparalyse (1)
- Hereditäre spastsiche Paraplegie (1)
- Heriditary sensor and motor neuropathy (1)
- Heriditäre sensomotorische Neuropathie (1)
- Herpesvirus 6 (1)
- Hirnblutung (1)
- Hirndruck (1)
- Hirnstimulation (1)
- Hirnödem (1)
- Hornhaut (1)
- Hyperalgesia (1)
- Hyperalgesie (1)
- IBA-1 (1)
- ICB (1)
- ICH (1)
- IL-15 (1)
- IL-22 binding protein isoform (1)
- IL-4 (1)
- IL22RA2 (1)
- IPND criteria (1)
- IVIG (1)
- IVIg (1)
- Identification (1)
- Idiopathisches Parkinson-Syndrom (1)
- IgG (1)
- IgG4 (1)
- Ih (1)
- Imaging (1)
- Immune cells (1)
- Immune system (1)
- Immunfluoreszenz (1)
- Immunmodulation (1)
- Immunoblot (1)
- Immunreaktion (1)
- Immunzellen (1)
- Impfung (1)
- Improvement (1)
- Infarkt (1)
- Infections (1)
- Inflamamtion (1)
- Influenza (1)
- Infrarotspektroskopie (1)
- Inherited neuropathies (1)
- Innervation (1)
- Insulin (1)
- Integrin (1)
- Integrin alpha-4 (1)
- IntelliCage (1)
- Interferon <beta-> (1)
- Interferon beta (1)
- Interleukin-18 (1)
- Interleukin-4 (1)
- Interleukin-6 (1)
- Interleukin-6-Deficient mice (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Intraepidermale Nervenfaserdichte (1)
- Intrathekale Applikation (1)
- Intravascular coagulation (1)
- Intrinsische Gerinnungskaskade (1)
- Ischemia (1)
- Ischämischer Schlaganfall (1)
- Ixolaris (1)
- JCV (1)
- K+ channel (1)
- K2P channels (1)
- KCNK5 (1)
- K\(_{2P}\)5.1 (1)
- Kaliumkanal (1)
- Kallikrein-Kinin-System (1)
- Kleinfaserneuropathie (1)
- Kleinfaseruntersuchungen (1)
- Kleinhirn (1)
- Knochentumor (1)
- Ko-inhibitorischer Signalweg (1)
- Kognition (1)
- Kognition bei mHE (1)
- Komplement <Immunologie> (1)
- Komplementsystem (1)
- Konfokale Mikroskopie (1)
- Konsolidierung (1)
- Kontrastmittel (1)
- Kopfschemata (1)
- Kortikobasales Syndrom (1)
- Kostimulation (1)
- Kreuzreaktivität (1)
- Kritische Flimmerfrequenz (1)
- L-DOPA (1)
- LI-rTMS (1)
- LIMP-2 (1)
- LSVT-big therapy (1)
- LVO (1)
- Ladder-Rung-Walking-Test (1)
- Laktat (1)
- Landouzy-Déjerine-Atrophie (1)
- Langzeitpotenzierung (1)
- Latenzänderung (1)
- Lebensqualität bei mHE (1)
- Lebensqualität nach stroke (1)
- Leukemia Inhibitory Factor (1)
- Lewy-Pathologie (1)
- Limb girdle muscular dystrophy (LGMD) (1)
- Liquor cerebrospinalis (1)
- Lokale Feldpotentialaktivität (1)
- Long COVID (1)
- Longitudinally extensive transverse myelitis (1)
- Lyme-Krankheit (1)
- Lyme-disease (1)
- Lymphozyten (1)
- Lymphozyten mediierter Angriff auf Neurone (1)
- Lysosomal storage disease (1)
- Ländliche Klinik (1)
- M-CSF (1)
- M. Fabry (1)
- M.Fabry (1)
- MDL-28170 (1)
- MIBG scintigraphy (1)
- MIC ligands (1)
- MMN (1)
- MMP9 (1)
- MOC fibers (1)
- MOG (1)
- MOG-IgG (1)
- MPZ (P0) (1)
- MRI criteria (1)
- MRI lesion study (1)
- MRT (1)
- MRT-Läsionsstudie (1)
- MSSS (1)
- Macrophages (1)
- Magnetic resonance imaging (1)
- Magnetic-resonance (1)
- Matched pairs (1)
- McDonald criteria (1)
- Mediated Inflammatory Hyperalgesia (1)
- Medium spiny neurons (1)
- Meige syndrome (1)
- Memory dysfunction (1)
- Meningoencephalitis (1)
- Meningoenzephalitis (1)
- Merkel cell density (1)
- Merkel cells (1)
- Merkelzelle (1)
- Mesencephal Locomotor Region (1)
- Mesenchymal stem/stromal cells (1)
- Mesenzephale Lokomotor Region (1)
- Methotrexate (1)
- Methyl-2 (1)
- Methylmalonsäure (1)
- Microarray (1)
- Middle cerebral artery infarction (1)
- Migräne (1)
- Mikroblutung (1)
- Mikroglia (1)
- Mikroglobulin <beta-2-> (1)
- Mikroneurographie (1)
- Mitoxantron (1)
- Miyoshi myopathy (1)
- Model (1)
- Molecular-weight heparin (1)
- Mononeuropathie (1)
- Monopolar depression (1)
- Morbus Parkinson (1)
- Morphologie <Biologie> (1)
- Motoneuron (1)
- Motoneuronen (1)
- Motor Control (1)
- Motor cortex (1)
- Motor learning (1)
- Motor nerve biopsy (1)
- Motor plasticity (1)
- Motoradaptation (1)
- Motorische Endplatte (1)
- Motorkonsolidierung (1)
- Mucopolysaccharidosis IIIa (1)
- Multiple Sclerosis Society of Canada (1)
- Multiplen Sklerose (1)
- Multisensorische Integration (1)
- Musikwahrnehmung (1)
- Muskel (1)
- Muskelhypertonie (1)
- Muster (1)
- Myasthenia gravis (1)
- Myatrophische Lateralsklerose (1)
- Mycobacterium caprae (1)
- Mycobacterium tuberculosis complex (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelinopathie (1)
- Myelinopathy (1)
- Myelinprotein (1)
- Myelitis (1)
- Myeloma (1)
- Myoblast (1)
- Myoblasten (1)
- Myopathie (1)
- Mysthenia Gravis (1)
- NADPH oxidase inhibitors (1)
- NAP-2 (1)
- NETs (1)
- NF-\(\kappa\)B (1)
- NF-κB (1)
- NKG2D (1)
- NKG2D ligands (1)
- NLG (1)
- NMO (1)
- NMO-IGG (1)
- NPC1 gene (1)
- NPC2 gene (1)
- NPSI (1)
- NaV1.9 (1)
- Nahinfrarot-Spektroskopie (1)
- Natriumkanal (1)
- Nav1.8 (1)
- Nav1.9 (1)
- Necrosis-factor-Alpha (1)
- Nerve growth-factorcopy (1)
- Nervenregeneration (1)
- Nervenregeneration ; Periphere Nervenverletzung ; Neuromuskuläre Krankheit ; Axonverletzung ; Entmarkung (1)
- Nervensonographie (1)
- Nervenultraschall (1)
- Nestin (1)
- Neuroborreliose (1)
- Neurodegenerative Erkrankung (1)
- Neurofascin-155-IgG4-(Para-)nodopathie (1)
- Neurofascin-155-IgM (1)
- Neurofeedback (1)
- Neurogenic inflammation (1)
- Neurogeriatrie (1)
- Neurologie (1)
- Neuromyelitis Optica (1)
- Neuromyelitis optica (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neuronale Ceroid Lipofuszinose (1)
- Neuropathic Pain (1)
- Neuroplastizität (1)
- Neuropsychologie (1)
- Neuropsychologischer Test (1)
- Neuroregeneration (1)
- Neurotrophe Faktoren (1)
- Neurotrophic Factors (1)
- Neurotrophic factors (1)
- Neurotrophine (1)
- Neutralisation <Chemie> (1)
- Neutrophil (1)
- NfL (1)
- Nicht-motorische Begleitsymptome (1)
- Nicotinischer Acetylcholinrezeptor (1)
- Niederfrequenzstimulation (1)
- Niemann–Pick disease type C (1)
- Nociceptor (1)
- Nodo-parandopathy (1)
- Nozizeptor (1)
- OCB (1)
- ON-Freezing (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Oncostatin-M-Receptor (1)
- Opioid receptor (1)
- Opioidrezeptor (1)
- Optical coherence tomography (1)
- Optikusnervenscheidendurchmesser (1)
- Orai2 (1)
- Oral anticoagulation (1)
- Osteopontin (1)
- Outcome (1)
- P300 Welle (1)
- PD-1 (1)
- PD-L1 (1)
- PF4 (1)
- PHES (1)
- PI3K isoforms (1)
- PML (1)
- PMP22 (1)
- PPAR-gamme (1)
- PREP (1)
- Pain questionnaire (1)
- Pain-related evoked potentials (1)
- Pan-Neurofascin-IgG3 (1)
- Paradoxical heat sensation (1)
- Paranodale und nodale Autoantikörper (1)
- Paranodopathie (1)
- Parkinson Krankheit (1)
- Parkinson's Disease (1)
- Parkinsons disease (1)
- Parkionson's disease (1)
- Partial Sciatic Transection (1)
- Passiv-Transfer (1)
- Pathomechanismus (1)
- Pathophysiologie (1)
- Patient Reported Outcome (1)
- Pedunculopontiner tegmentaler Nukleus (1)
- Perfusion (1)
- Peripheral Inflammation (1)
- Periphere Nerven (1)
- Periphere mononukleäre Zellen (1)
- Pharmacological management (1)
- Phosphodiesterasehemmer (1)
- Photothrombotic Stroke (1)
- Physiotherapie (1)
- Pilzkörper (1)
- Plasma extravasation (1)
- Plasmakallikrein (1)
- Plasmakallikrein ischämischer Schlaganfall (1)
- Plastizität (1)
- Platelets (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Pointing error (1)
- Polyneuropathy (1)
- Pregnancy (1)
- Procalcitonin (1)
- Prodigy (1)
- Prognose (1)
- Prognostik (1)
- Progressive supranuclear palsy (1)
- Proton Magnetic Resonance Spectroscopy (1)
- Protonen (1)
- Protonenspektroskopie (1)
- Psychologische Diagnostik (1)
- Psychophysik (1)
- QSART (1)
- QST (1)
- Quality of life (1)
- Quantitativ Sensorische Testung (1)
- Quantitative Sensorische Testung (1)
- Quantitativer sudomotorischer Axonreflextest (1)
- R-715 (1)
- RAG-1 (1)
- RECK (1)
- RKIP (1)
- RNA extraction (1)
- RT-PCR (1)
- Randomized controlled trial (1)
- Randomized controlled-trial (1)
- Ranvier'sche Schnürringe (1)
- Rasmussen-Syndrom (1)
- Rat (1)
- Rat Sensory Neurons (1)
- Rats (1)
- Ratte (1)
- Raumwahrnehmung (1)
- Receptors (1)
- Regeneration (1)
- Regenerative medicine (1)
- Regulatorische T-Zellen (1)
- Regulatory T cells (1)
- Resilienz (1)
- Respiratory insufficiency (1)
- Retinal degeneration (1)
- Revaskularisierung (1)
- Rheumatoid-Arthritis (1)
- Rho-GTPase Cdc42 (1)
- Rhombencephalitis (1)
- Rhythmusperzeption (1)
- Richardson-Olszewski-Syndrome (1)
- Rituximab (1)
- Rochester diabetic neuropathy (1)
- SARS-CoV (1)
- SB332235 (1)
- SERCA (1)
- SGLT2 inhibitors (1)
- SHRSP (1)
- SMA (1)
- SNI (1)
- SOD1 mutations (1)
- SPECT (1)
- SPG17 (1)
- SPG4 (1)
- SREBP (1)
- STAIR (1)
- STDT (1)
- STEMI (1)
- Sars-CoV-2 (1)
- Schlaganfall-Netzwerk (1)
- Schmerz-assoziierte elektrisch evozierte Potentiale (1)
- Schmerz-assoziierte evozierte Potenziale (1)
- Schmerzerfassung (1)
- Schmerzforschung (1)
- Schmerzfragebogen (1)
- Schmerzzeichnungen (1)
- Schreibkrampf (1)
- Schub (1)
- Schwann Zellen (1)
- Schwann cell dedifferentiation (1)
- Schwann cell differentiation (1)
- Schwann cells (1)
- Schwann-cells (1)
- Schwann´sche Zelle (1)
- Schweißdrüse (1)
- Schädel-Hirn-Trauma (1)
- Score (1)
- Screening questionnaire (1)
- Secondary stroke prevention (1)
- Sekundärprävention (1)
- Sensitivity (1)
- Sensorik <Neurophysiologie> (1)
- Serotonin-Reuptake-Hemmer (1)
- Sigaltransduktionsweg (1)
- Signaltransduktion (1)
- Silver-syndrome (1)
- Sjorgens-syndrome (1)
- Skelettmuskel (1)
- Skin biopsy (1)
- Small Fiber Neuropathie (1)
- Small fiber dysfunction (1)
- Small-fiber neuropathy (1)
- Sonic hedgehog (1)
- Sonographie (1)
- Sphingosine 1-Phosphate (1)
- Spinalganglienneuron (1)
- Stammganglienblutung (1)
- Stenosis degree (1)
- Stenosis length (1)
- Stent (1)
- Stereologie (1)
- Stiff-Person-Syndrom (1)
- Stim (1)
- Stimuli (1)
- Striatum (1)
- Stroke Manager (1)
- Stroke-Unit (1)
- Subarachnoid (1)
- Subarachnoid hemorrhage (1)
- Subarachnoidalblutung (1)
- Suralisbiopsien (1)
- Suralisneurographie (1)
- Survey (1)
- Synapse (1)
- Synaptic plasticity (1)
- System involvement (1)
- T cell activation (1)
- T cell line (1)
- T lymphocyte (1)
- T- Lymphozyt (1)
- T-PA (1)
- T-cell epitope (1)
- T-cell repertoire (1)
- T-cells (1)
- T-lymphocyte (1)
- T-zell epitope (1)
- T-zell repertoir (1)
- TAP Alertness (1)
- TASK2 (1)
- TBI (1)
- TIMP-1 (1)
- TIND (1)
- TLO (1)
- TMS (1)
- TNF (1)
- TNF alpha (1)
- TNF-R1 (1)
- TNF-R2 (1)
- TNF-Rezeptor-1 (1)
- TNF-Rezeptor-2 (1)
- TNF-receptor-1 (1)
- TNF-receptor-2 (1)
- TNF-receptors (1)
- TNF-α (1)
- TNFα (1)
- TOR1A (1)
- TRP (1)
- TRP Channels (1)
- TRPV 1 (1)
- TSPO (1)
- Tdp-43 (1)
- Telemedizin (1)
- Temporal Discrimination Threshold (1)
- Therapy (1)
- Thermal Hyperalgesia (1)
- Thrombektomie (1)
- Thrombo-inflammation (1)
- Thromboinflammation (1)
- Thrombolyse (1)
- Thrombozyt (1)
- Thrombus (1)
- Thrombus formation (1)
- Thymom (1)
- Tiefe Hirnstimulation (1)
- Topiramat (1)
- Topiramate (1)
- Tor1a (1)
- Torticollis (1)
- Training (1)
- Transkranielle Magnetstimulation (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Trauma (1)
- Trem2 (1)
- Trepanation (1)
- Triamcinolon (1)
- Trick (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- Tuberkulose (1)
- Tumor-Nekrose-Faktor (1)
- Tumor-Nekrose-Faktor <alpha> (1)
- Tumor-Nekrose-Faktor <alpha>-Inhibitor (1)
- Type 1 diabetes (1)
- Umfragestudie (1)
- Ureaplasma species (1)
- Urämie (1)
- VCAM (1)
- VCAM-1 (1)
- VR1 (1)
- Vaccination (1)
- Vascular system (1)
- Vaskulitische Polyneuropathie (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Venlafaxin (1)
- Verbesserung (1)
- Vergleich (1)
- ViMS (1)
- Viral (1)
- Virus (1)
- Visuomotorisches Lernen (1)
- Vitamin D (1)
- Vitamin D-Mangel (1)
- Vitamin-B12-Mangel (1)
- Volon A (1)
- Von-Willebrand-factor (1)
- Western blot (1)
- White matter lesions (1)
- Wiederbelebung (1)
- Wingerchuk criteria 2006 and 2015 (1)
- Wissenschaftlicher Nachwuchs (1)
- Würzburg / Universität Würzburg (1)
- X-Chromosom (1)
- X-Inaktivierung (1)
- X-chromosomal inactivation (1)
- XAV-939 (1)
- ZNS (1)
- Zeitwahrnehmung (1)
- Zellkultur (1)
- Zentralnervensystems (1)
- Zonula Occludens-1 (1)
- Zytokin (1)
- [18F]FDG positron emission tomography (1)
- abciximab (1)
- acid sphingomyelinase (1)
- activation (1)
- activity-dependent slowing (1)
- acute lymphoblastic leukaemia (1)
- acute management of stroke (1)
- acute neurology (1)
- acute stroke imaging (1)
- acute stroke management (1)
- acute stroke outcome (1)
- adhesion molecules (1)
- adrenal medulla (1)
- adsorption (1)
- adult-onset (1)
- advanced therapy medicinal products (1)
- afferents (1)
- age (1)
- aggression (1)
- agrin (1)
- albumin (1)
- algorithm (1)
- alias pilot trial (1)
- allodynia (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- alpha-galactosidase A (1)
- alpha‐synuclein (1)
- alpha‐synuclein propagation (1)
- alpha‐synuclein seeding (1)
- amitriptyline (1)
- amygdala (1)
- amyloidosis (1)
- amyotrophe Lateralsklerose (1)
- amyotrophic lateral sclerosis (1)
- amyotrophic lateral sclerosis (ALS) (1)
- analgesia (1)
- analgesic medication (1)
- aneurysm surgery (1)
- angiography (1)
- animal behavior (1)
- ankles (1)
- anodic stimulation (1)
- antagomir (1)
- anthropometric measurement (1)
- anthropometric measurements (1)
- anti-Amphiphysin Antikörper (1)
- anti-amphiphysin antibodies (1)
- anti-aquaporin-4 antibody (1)
- anti-contactin-1 (1)
- antibody (1)
- anticoagulants (1)
- antidepressants (1)
- antigen-presenting cells (1)
- antithrombotic (1)
- apoE (1)
- apoe (1)
- apomorphine (1)
- apoplexy (1)
- aquaporin 4 (1)
- aquaporin-4 autoantibodies (1)
- areas (1)
- arm (1)
- artery occlusion (1)
- asomatognosia (1)
- assistive devices (1)
- association (1)
- association studies in genetics (1)
- assoziative Paarstimulation (1)
- astrocyte (1)
- astrocytes (1)
- astrogliosis (1)
- atherosclerosis (1)
- atrophy Kennedys-disease (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attenuation of disease (1)
- atypical chemokine receptor 3 (1)
- auditorisches Neurofeedback Training (1)
- auditory (1)
- autoantibody (aAb) (1)
- autoantigen (1)
- autoimmune encephalitis (1)
- autoimmune neuroinflammation (1)
- autoimmune nodopathy (1)
- autoimmunität (1)
- autophagy (1)
- autoradiography (1)
- axon growth (1)
- axon guidance molecules (1)
- axonal degeneration (1)
- axonal integrity (1)
- axonal transcriptome (1)
- axonal transport (1)
- axonopathic changes (1)
- back pain (1)
- barrier (1)
- barrier integrity (1)
- basal forebrain cholinergic neurons (1)
- basal ganglia hemorrhage (1)
- behavioral disorders (1)
- beta oscillation (1)
- beta power (1)
- beta2 Mikroglobulin knock-out Mäuse (1)
- beta2 microglobulin knock-out mice (1)
- bilateral internal carotid artery stenosis (1)
- bilateral motor network (1)
- binding analysis (1)
- biological locomotion (1)
- biopsies (1)
- blood (1)
- blood CSF barrier (1)
- blood coagulability (1)
- blood coagulation (1)
- blood nerve barrier (1)
- blood sedimentation (1)
- body diagram (1)
- body ownership (1)
- bone (1)
- bone-marrow (1)
- botulinum neurotoxin (1)
- botulinum toxin (1)
- bradykinesia (1)
- bradykinin (1)
- brain dynamics (1)
- brain edema (1)
- brain endothelium (1)
- brain metabolic alterations (1)
- brain networks (1)
- brain state (1)
- brain stem (1)
- burning pain (1)
- bystander activation (1)
- c-fibre (1)
- calpain (1)
- capsaicin (1)
- cardiac imaging (1)
- cardiac magnetic resonance imaging (1)
- cardiovascular disease (1)
- care (1)
- care tempis (1)
- caregiver (1)
- caudate nucleus (1)
- celiac disease (1)
- cell adhesion (1)
- cell binding assay (1)
- cellular therapy (1)
- cerebellar vermis hypoplasia (1)
- cerebellum (1)
- cerebral arteries (1)
- cerebral blood flow (1)
- cerebral endothelial cell (1)
- cerebral endothelial cells (1)
- cerebral inflammation (1)
- cerebral microbleeds (1)
- cerebral small vessel disease (1)
- cerebrale Ischämie (1)
- cerebrospinal fluid culture (1)
- cerebrospinal-fluid (1)
- cerebrovascular diseases (1)
- chitinase-3-like protein 1 (1)
- choline acetyltransferase (1)
- cholinergic activity (1)
- cholinergic system (1)
- chronic constriction nerve injury (1)
- chronic constriction nerve injury (CCI) (1)
- chronic heart failure (1)
- chronic inflammatory demyelinating polyneuropathy (1)
- chronic stimulation (1)
- chronic stress (1)
- chronische Multiple Sklerose (1)
- circuitopathies (1)
- classification (1)
- claudin-1 (1)
- clinical approach (1)
- clinical diagnosis (1)
- clinical neurology (1)
- clinical outcome (1)
- clinical phenotype (1)
- clip control (1)
- closed-loop (1)
- cluster analysis (1)
- co-inhibitory signalling (1)
- coagulation (1)
- coagulation factor XIIa (1)
- cochlea (1)
- cognitive (1)
- cognitive decline (1)
- cognitive function (1)
- coherence (1)
- coherence analysis (1)
- collagens (1)
- collateral circulation (1)
- colony stimulating factor 1 (1)
- compensatory strategies (1)
- complement deposition (1)
- complex regional pain syndrome (1)
- comprehension (1)
- computed tomography (1)
- computer vision (1)
- computerized tomography (1)
- contact activation system (1)
- contactin-associated protein 1 (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- contrast-enhanced MRI (1)
- contrastmedium (1)
- conversion (1)
- coordination (1)
- coping (1)
- corneale confocale Mikroskopie (1)
- cortical activation (1)
- cortical excitability (1)
- cortical oscillatory activity (1)
- cortical pathology (1)
- cortical silent period (1)
- cortico-striatal synapse (1)
- corticobasal syndrome (1)
- costimulation (1)
- critical flimmer frequency (1)
- crossover trial (1)
- crush (1)
- cue (1)
- cutaneous innervation (1)
- cutaneous patch (1)
- cutting edge (1)
- dSPN (1)
- dSTORM (1)
- damage cool aid (1)
- darbepoetin alpha (1)
- data filtering (1)
- decompressive hemicraniectomy (1)
- decreasing autonomy (1)
- deep brain stimulation (DBS) (1)
- deep brain-stimulation (1)
- dekompressive Hemikraniektomie (1)
- delayed cerebral infarction (1)
- delays progression (1)
- demography (1)
- demyelinating disease (1)
- demyelinating polyneuropathy (1)
- demyelinating polyradiculoneuropathy (1)
- dendric cells (1)
- dendritic cells (1)
- dendritische Zellen (1)
- dermal B cells (1)
- design (1)
- developmental signaling (1)
- diabetes mellitus (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diagnostic medicine (1)
- diagnostics (1)
- diapedesis (1)
- diffuse (1)
- digital medicine (1)
- direct pathway (1)
- directional deep brain stimulation (1)
- disease model (1)
- disease progression (1)
- disease severity (1)
- disease-modifying therapy (1)
- disorder (1)
- domain potassium channels (1)
- dopamine acetylcholine (1)
- dopamine transporter (DAT) (1)
- dopaminergic cells (1)
- dorsal root ganglion neuron (1)
- drug (1)
- duodenal levodopa infusion (1)
- dysferlinopathy (1)
- early-onset isolated dystonia (1)
- edoxaban (1)
- effects (1)
- efficacy (1)
- ejection fraction (1)
- elderly (1)
- electroencephalography (1)
- electromyography (1)
- element (1)
- embolic stroke (1)
- emergency care (1)
- emotion (1)
- emulsions (1)
- encephalitis (1)
- endothelin-1 (1)
- endotheliopathy (1)
- enteropathy (1)
- enzyme assays (1)
- enzyme-linked immunoassays (1)
- epidermis (1)
- epitope (1)
- etanercept (1)
- event-related desynchronization (1)
- evoked potentials (1)
- excitability (1)
- exome sequencing (1)
- experimental (1)
- experimental autoimmune neuritis (1)
- experimental design (1)
- expert opinion (1)
- extensiv transverse myelitis (1)
- extracellular domain (1)
- eye movement disorders (1)
- fMRI Analyse (1)
- facial pain (1)
- factor XI (1)
- familial amyloidotic polyneuropathy (1)
- family caregiver (1)
- fatigue (1)
- fear (1)
- fear memory (1)
- feasibility (1)
- feeling of bodily self (1)
- female Fabry patients (1)
- females (1)
- fetal (1)
- fibers (1)
- fibroblast (1)
- fibromyalgia sydrome (1)
- fine-mapping (1)
- finger-tapping task (1)
- finger-tapping task (FTT) (1)
- fingolimod (1)
- flotillin-1 lipid rafts (1)
- fluorine (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral ischemia (1)
- focal cerebral-ischemia (1)
- fokale Dystonie (1)
- fosfomycin (1)
- fractionator (1)
- free radical scavenger (1)
- freezing of gait (FOG) (1)
- fullerenes (1)
- functional MRI (1)
- functional connectivity (1)
- functional neuroanatomy (1)
- functional status (1)
- fungal infection (1)
- future directions (1)
- gadofluorine (1)
- gadolinium-DTPA (1)
- gait modulation (1)
- gait-phase prediction (1)
- galactomannan (1)
- gender (1)
- gene mutations (1)
- gene variant (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- gene-environmental interaction (1)
- generalized cerebellar atrophy (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- gephyrin (1)
- geste (1)
- giant cell arteritis (1)
- glia (1)
- glial damage (1)
- glioblastoma multiforme (1)
- globus pallidus (1)
- globus pallidus pars interna (GPi) (1)
- glucocerebrosidase mutation (1)
- glycation end products (1)
- glycine receptor (GlyR) (1)
- glycine receptor autoantibodies (1)
- glycoprotein Ib (1)
- glycoprotein VI (1)
- glycoprotein receptor Ibα (1)
- glycosylation (1)
- granzyme B (1)
- gridle muscular-dystrophy (1)
- growth (1)
- growth pattern (1)
- gustatory dysfunction (1)
- health behavior (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hemicraniectomy (1)
- hemoglobin (1)
- hemorrhagic transformation (1)
- heparin (1)
- hereditary motor and sensory neuropathy (1)
- hereditary neuropathy (1)
- hereditary spastic paraplegia (1)
- hereditary spastic paraplegia (HSP) (1)
- hereditäre Neuropathien (1)
- hereditäre periphere Neuropathie (1)
- hereditäre sensomotorische Neuropathie (1)
- hernia repair (1)
- hexanucleotide repeat (1)
- high contrast (1)
- hip (1)
- hippocampus (1)
- histology (1)
- homotypic fusion and protein sorting (1)
- hospitals (1)
- human (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human muscle-cells (1)
- human neurons (1)
- humans (1)
- hyperalgesia (1)
- hypercholesterolemia (1)
- hyperekplexia (1)
- hypothermia (1)
- hypoxic-ischemic encephalopathy (1)
- hypoxische Enzephalopathie (1)
- i.v. thrombolysis (1)
- iNOS-Synthase (1)
- iPSC (1)
- idiopathic inflammatory myopathies (1)
- image quality (1)
- image-guided programming (1)
- imaging (1)
- immaturity (1)
- immune (1)
- immune-response (1)
- immunisation (1)
- immunofluorescence (1)
- immunofluoreszenz (1)
- immunoglobulin-G (1)
- immunzellen (1)
- implants (1)
- in-vivo (1)
- incidence (1)
- increased risk (1)
- induced neural stem cells (1)
- inducible expression (1)
- inducible nitric oxide synthase (1)
- inebilizumab (1)
- inertial measurement units (1)
- infantile neuronal ceroid lipofuscinosis (1)
- infarction size (1)
- infarction volume (1)
- infection (1)
- inflammatory cascades (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory pain (1)
- informal care (1)
- informal caregiving (1)
- informed consent (1)
- inherited metabolic disorders (1)
- inherited peripheral neuropathy (1)
- injection site reactions; (1)
- innate immune system (1)
- innervation (1)
- integrin α2 (1)
- integrins (1)
- intensity of attention (1)
- interference (1)
- interleukin-1 receptor antagonist (1)
- interleukin-8 (1)
- internal carotid artery stenosis (1)
- internal globus pallidus (1)
- internal medicine (1)
- internet-based intervention (1)
- interval timing (1)
- interview (1)
- intra-limb anticipatory postural adjustments (1)
- intracerebral hemorrhage (1)
- intracranial bleeding (1)
- intracranial hemorrhage (1)
- intractable hiccup (1)
- intraepidermal nerve fiber density (1)
- intraepidermal nerve fibre density (1)
- intraoperative (1)
- intrathecal (1)
- intrathecal application (1)
- intrathekal (1)
- intravenous immunoglobulin (1)
- intravenous thrombolysis (1)
- invasive electric stimulation (1)
- ipsilateral motor evoked potential (1)
- ipsilateral motor network (1)
- iron (1)
- iron dyshomeostasis (1)
- iron oxide nanoparticles (1)
- ischemia (1)
- ischemia/reperfusion injury (1)
- ischemic cascade (1)
- kallikrein-kinin system (1)
- kallikrein–kinin system (1)
- kinesthesia (1)
- kinin receptor (1)
- kinin receptors (1)
- kleinkalibrige Nervenfasern (1)
- knees (1)
- knockout (1)
- large vessel occlusion (1)
- latency shift (1)
- learning (1)
- levodopa (1)
- levodopa-induced dyskinesia (1)
- linkage (1)
- liponeurocytoma (1)
- locomotion (1)
- locomotor network (1)
- long-term pain (1)
- longitudinally extensive transverse myelitis (1)
- lymphokine-activated killer (1)
- lyso-Gb3 (1)
- lysosomal dysfunction (1)
- lysosomal enzyme (1)
- lysosomal storage disease (1)
- lyso‐Gb3 (1)
- mRNA expression (1)
- magnesium (1)
- makrophagen (1)
- malignant middle cerebrial artery infarction (1)
- maligner Mediainfarkt (1)
- management (1)
- mast cells (1)
- matrix metalloproteinases (1)
- mechanical energy (1)
- mechanisms (1)
- medial ganglionic eminence (1)
- medication therapy failure (1)
- medikamentöse Sekundärprävention bei stroke (1)
- medulloblastoma (1)
- memory (1)
- meningoencephalitis (1)
- mental health (1)
- mental rotation (1)
- mesenchymal stem and stromal cells (1)
- mesenchymal stem cells (1)
- metaanalysis (1)
- methylphenidate (1)
- miR-182-5p (1)
- miRNA expression patterns (1)
- miRNA polymorphisms (1)
- miRNA-based analgesic (1)
- miRNA-based diagnostics (1)
- mice impact (1)
- microangiopathy (1)
- microscopy (1)
- microsphere/macrosphere (1)
- microtubules (1)
- midbrain (1)
- migraine (1)
- migraineur (1)
- minimal hepatische Enzephalopathie (1)
- minocycline (1)
- mixed fiber neuropathy (1)
- mixed methods (1)
- molecular biology (1)
- molecular mechanism (1)
- molecular mimicry (1)
- molecular signature (1)
- monocycline (1)
- monocytes (1)
- monomethyl fumarate (1)
- morphology (1)
- motoneuron (1)
- motoneuron disease (1)
- motor (1)
- motor axonal neuropathy (1)
- motor cortex (1)
- motor evoked potential (MEP) (1)
- motor function (1)
- motor neuron disease (1)
- motor neuropathy (1)
- motor proteins (1)
- motor-evoked potentials (MEP) (1)
- motorisches Lernen (1)
- mouse (1)
- mouse brain microvascular endothelial cell cultur (1)
- movement (1)
- movement disorder (1)
- movements (1)
- multiple sklerosis (1)
- multisensorische Integration (1)
- multisensory integration (1)
- muscle atrophy (1)
- muscle strength (1)
- mushroom-body (1)
- musikalische Syntax (1)
- musk myasthenia gravis (1)
- myasthenia gravis (1)
- myelin biology and repair (1)
- myelin protein zero (1)
- myelination (1)
- myoblast (1)
- myocardial infarction (1)
- myopathy (1)
- nACh-Rezeptor (1)
- natalizumab (1)
- natural history (1)
- natural killer cells (1)
- near infrared spectroscopy (1)
- near-infrared spectroscopy (1)
- neonatal meningitis (1)
- nerve conduction studies (1)
- nerve tumor (1)
- nerve-fibers (1)
- nervous system (1)
- nervous-system (1)
- neural apoptosis (1)
- neural biomarkers (1)
- neural stem cell (1)
- neural stem cells (1)
- neuralgia (1)
- neurobehavioural deficits (1)
- neuroborreliosis (1)
- neurocritical care (1)
- neurocytoma (1)
- neurofilaments (1)
- neurogen (1)
- neuroleukemiosis (1)
- neurological (1)
- neurological complications (1)
- neurological examination (1)
- neuromelanin (1)
- neuromuskuläre Endplatte (1)
- neuronal apoptosis (1)
- neuronal ceroid lipofuscinosis (1)
- neuronal differentiation (1)
- neuronal network (1)
- neuronal stem cells (1)
- neurone (1)
- neuronopathy (1)
- neurophysiology (1)
- neuroplasticity (1)
- neuropsychology (1)
- neuroregeneration (1)
- neurorepair (1)
- neurotrophins (1)
- neutralization (1)
- neutrophil (1)
- nicotinamide (1)
- nicotinic receptors (1)
- nociceptive Schwann cells (1)
- nociceptor sensitization (1)
- node of ranvier (1)
- nodes of Ranvier (1)
- non-motor features (1)
- nonalcoholic steatohepatitis (1)
- noradrenalin (1)
- noradrenaline (1)
- norepinephrine (1)
- novo renal transplantation (1)
- nucleus ventralis intermedius (1)
- nystagmus (1)
- object recognition memory (1)
- obstacle avoidance (1)
- occlusion (1)
- olfactory dysfunction (1)
- olfactory testing (1)
- oligodendroglia (1)
- on-site examination (1)
- online systems (1)
- ontactin 1 (1)
- opioid (1)
- opioidreceptor (1)
- optic nerve sheath diameter (1)
- optic neuritis (1)
- optical coherence tomography (1)
- orofacial pain (1)
- orofazialer Schmerz (1)
- oscillations (1)
- outcome (1)
- outer hair cell (OHC) (1)
- oxidative stress (1)
- p.R245H (1)
- p.S298P (1)
- p38 mitogen-activated protein kinase (1)
- p57kip2 (1)
- pain drawings (1)
- pain pattern (1)
- pain related evoked potentials (1)
- pain sensation (1)
- pain-associated behavior (1)
- paired associative stimulation (1)
- pallidal stimulation (1)
- pandemic (1)
- paranode (1)
- paranodopathy (1)
- paraparesis (1)
- parkinson disease (1)
- parkinsons disease (1)
- passiv transfer (1)
- pathology section (1)
- pathophysilogical mechanisms (1)
- pathophysiology (1)
- pathway analysis (1)
- pathways (1)
- patient reported outcome measures (1)
- patient triage (1)
- pattern (1)
- pedunculopontine nucleus (PPN) (1)
- pegylated insulin-like growth factor 1 (1)
- peptide (1)
- periperal nerve (1)
- peripheral injury (1)
- peripheral nerve (1)
- peripheral nerve injury (1)
- peripheral nerve involvement (1)
- peripheral nerve trauma (1)
- peripheral nerves (1)
- peripheral nervous-system (1)
- permanent and transient middle cerebral artery occlusion (1)
- pet (1)
- ph (1)
- pharmacology (1)
- phosphodiesterase inhibitor (1)
- phosphorylated tau protein (1)
- physical therapy modalities (1)
- physiology (1)
- pilot project (1)
- placebo-controlled (1)
- plaque cross-sectional area (1)
- plasma extravasation (1)
- plasma oxysterols (1)
- plasminogen (1)
- plasticity (1)
- platelet activation (1)
- platelet aggregation (1)
- pleasant touch (1)
- point-of-care echocardiography (1)
- pointing task (1)
- polymorphism (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- population-based (1)
- position estimation (1)
- post-processing (1)
- post-traumatic stress disorder (1)
- postherpetic neuralgia (1)
- postural control (1)
- posture (1)
- potassium channels (1)
- potent inducer (1)
- precision medicine (1)
- predictive coding (1)
- prednisone (1)
- prefrontal cortex (1)
- premotor cortex (1)
- presynaptic inhibition (1)
- preterm birth (1)
- preventive treatment (1)
- procalcitonin (1)
- progression (1)
- progressive ataxia (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- progressive multiple sclerosis (1)
- progressive supranuclear palsy (1)
- proinflammatory cytokine (1)
- protein and mRNA expression (1)
- proteins (1)
- proteolipid protein (1)
- proteolipid protein gene (1)
- proteomics (1)
- protons (1)
- prä-post Design (1)
- prämotorischer Cortex (1)
- psychiatric disorders (1)
- psychological support (1)
- psychosocial resilience (1)
- purmorphamine (1)
- putamen (1)
- quality (1)
- quality control (1)
- quality of life (QoL) (1)
- quality-control (1)
- qutenza (1)
- randomized controlled double-blind study (1)
- rasmussen encephalitis (1)
- rat brain microvascular endothelial cell culture (1)
- rat hepatocytes (1)
- rats (1)
- reach-to-grasp movement (1)
- reaction-time tasks (1)
- receptor (1)
- receptor tyrosine kinase (1)
- recombinant tissue-type plasminogen activator (1)
- recommendations (1)
- recovery (1)
- recurrence (1)
- reflex (1)
- regeneration (1)
- regional heterogeneity (1)
- regulation (1)
- regulatorische T Zellen (1)
- regulatory cells (1)
- reinnervation (1)
- relapsing multiple sclerosis (1)
- relapsing-remitting multiple sclerosis (1)
- religiosity (1)
- renal function (1)
- reoxygenation (1)
- reperfusion (1)
- reperfusion injury (1)
- reproducible outcome measure (1)
- reserpinized rat model (1)
- resilience (1)
- responsivity (1)
- retinal ganglion cells (1)
- retinocochleocerebral (1)
- retrograde Marker (1)
- retrograde tracers (1)
- rett (1)
- rhythm perception (1)
- rhythmperception (1)
- risk (1)
- risk factors (1)
- risk of fall (1)
- rt-PA (1)
- rural clinics (1)
- rutabaga (1)
- safety and tolerability (1)
- scale (1)
- schmerz-assoziierte elektrisch-evozierte Potenziale (1)
- sciatic nerve (1)
- sciatic nerve injury (1)
- sciatic nerves (1)
- search filter (1)
- secondary infarct growth (1)
- secretome (1)
- segmental centers of mass (1)
- sensomotorisch (1)
- sensory (1)
- sensory neurons (1)
- seronegative (1)
- seropositive (1)
- serotonin (1)
- serotonin transporter (1)
- serum (1)
- sex addiction (1)
- shedding (1)
- shingles (1)
- siRNA (1)
- signal peptide (1)
- signal transduction pathway (1)
- simulation training (1)
- single photon emission computed tomography (SPECT) (1)
- skewed (1)
- skilled forelimb movements (1)
- skin cells (1)
- skin diseases (1)
- skin tumors (1)
- small fiber tests (1)
- small molecule (1)
- small nerve fibers (1)
- small nerve fibres (1)
- small vessel disease (1)
- small-fiber neuropathy (1)
- small-fiber-Neuropathie (1)
- small-molecule Inhibitoren (1)
- small-molecule inhibitors (1)
- socioeconomic status (1)
- software (1)
- soleus muscles (1)
- soluble endoglin (1)
- somatic resilience (1)
- somatosensory temporal discrimination (1)
- somatosensory-evoked-potentials (1)
- spannungsgesteuerter Natriumkanal (1)
- spatial attention (1)
- sphingolipids (1)
- spinal muscular atrophy (1)
- spinal-cord (1)
- spinal-cord-injury (1)
- startle disease (1)
- stenosis (1)
- stent-retriever device (1)
- steroids (1)
- stiff-person syndrome (SPS) (1)
- stimulation (1)
- stimulationsinduzierte Plasitzität (1)
- store-operated Ca2+ entry (1)
- stress (1)
- striatal dopaminergic dysregulation (1)
- stroke management (1)
- stroke networks (1)
- stromal cells (1)
- study (1)
- subarachnoid hemorrhage (1)
- subcutaneous injection (1)
- substance-P (1)
- subthalamic nucleus (STN) (1)
- sural nerve (1)
- survey (1)
- swimming (1)
- switch (1)
- symptom control (1)
- symptom-specific treatment (1)
- synapse (1)
- synaptic plasticity (1)
- synaptic transmission (1)
- syndrome (1)
- system (1)
- systematic review (1)
- systemic inflammation (1)
- systolic dysfunction (1)
- target considerations (1)
- task retention (1)
- telemedicine network (1)
- temporal discrimination threshold (1)
- teriflunomide (1)
- term follow-up (1)
- tetrahydroisoquinoline derivates (1)
- tetraparesis (1)
- threshold discrimination identification test (1)
- thrombemboli (1)
- thromboemboli (1)
- thromboembolic clot model (1)
- thromboembolic stroke (1)
- thromboinflammation (1)
- thrombolysis (tPA) (1)
- thrombus formation (1)
- thymoma (1)
- tics (1)
- tiefe Hirnstimulation (1)
- time (1)
- timing (1)
- tissue resident T cells (1)
- tissue-plasminogen activator (1)
- tnf (1)
- tolerance (1)
- toleranz (1)
- tool (1)
- topography (1)
- torsinA (1)
- torticollis (1)
- transcranial direct current stimulation (1)
- transcranial magnetic simulation (TMS) (1)
- transgenic mouse model (1)
- transient middle cerebral artery (1)
- transient middle cerebral artery occlusion model (1)
- transient receptor potential vanilloid 1 (TRPV1) (1)
- transkranielle Gleichstromstimulation (tDCS) (1)
- translation (1)
- translational research (1)
- translational stroke research (1)
- transmission electron microscopy (1)
- treatment options (1)
- treatment-induced neuropathy in diabetes (TIND) (1)
- treatment-resistant depression (1)
- triamcinolone acetonide (1)
- trick (1)
- trigeminal nerve (1)
- trigeminal neuropathy (1)
- troponin (1)
- tuberculous meningitis (1)
- tumor (1)
- tumor immunity (1)
- tumor necrosis factor-α (1)
- ultrasound imaging (1)
- under-dosing (1)
- up-regulation (1)
- upper limb (1)
- validation (1)
- variants of unknown significance (1)
- vascular cell adhesion molecule-1 (1)
- vascular dementia (1)
- vascular homeostasis (1)
- vascular permeability (1)
- vasculopathy (1)
- venlafaxine (1)
- versus (1)
- vertebrobasilar insufficiency (1)
- vertebrobasilar stroke (1)
- vertigo (1)
- vessel patency (1)
- vestibular (1)
- videooculography (1)
- virtual reality (1)
- visual activity (1)
- visual pathways (1)
- visuoadaptive motor task (1)
- visuomotorisches Lernen (1)
- volume regulation (1)
- vs (1)
- weight drop (1)
- white blood cells (1)
- white matter disease (1)
- white matter hyperintensities (1)
- white matter lesions (1)
- zeitliche Wahrnehmungsschwellen (1)
- zerebelläre Gleichstromstimulation (1)
- zerebrale Endothelzelle (1)
- zerebrale Endothelzellen (1)
- Ältere (1)
- α-Galactosidase A (1)
- α-Synuclein (1)
- α-synuclein-specific T cells (1)
- α‐GalA 3D‐structure (1)
- β-APP (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Neurologische Klinik und Poliklinik (524)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (26)
- Graduate School of Life Sciences (19)
- Neurochirurgische Klinik und Poliklinik (18)
- Medizinische Klinik und Poliklinik I (17)
- Institut für Klinische Epidemiologie und Biometrie (16)
- Institut für Klinische Neurobiologie (16)
- Rudolf-Virchow-Zentrum (16)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (14)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (13)
Schriftenreihe
Sonstige beteiligte Institutionen
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Institut für Musikphysiologie und Musiker-Medizin der Hochschule für Musik, Theater und Medien, Hannover (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Interdisziplinäres Amyloidosezentrum Nordbayern (1)
- KfH Nierenzentrum (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Politecnico di Milano (1)
- Sahin Lab, F.M. Kirby Neurobiology Center Boston Children’s Hospital, Department of Neurology, Harvard Medical School (1)
- Wurzburg Fabry Center for Interdisciplinary Therapy (FAZIT), Wurzburg, Germany (1)
- Würzburg Fabry Center for Interdisciplinary Therapy (FAZIT), University of Würzburg, Würzburg, Germany (1)
Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy
(2020)
[\(^{18}\)F]fluorodeoxyglucose (FDG) PET and [\(^{123}\)I]metaiodobenzylguanidine (MIBG) scintigraphy may contribute to the differential diagnosis of neurodegenerative parkinsonism. To identify the superior method, we retrospectively evaluated 54 patients with suspected neurodegenerative parkinsonism, who were referred for FDG PET and MIBG scintigraphy. Two investigators visually assessed FDG PET scans using an ordinal 6-step score for disease-specific patterns of Lewy body diseases (LBD) or atypical parkinsonism (APS) and assigned the latter to the subgroups multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal syndrome. Regions-of-interest analysis on anterior planar MIBG images served to calculate the heart-to-mediastinum ratio. Movement disorder specialists blinded to imaging results established clinical follow-up diagnosis by means of guideline-derived case vignettes. Clinical follow-up (1.7 +/- 2.3 years) revealed the following diagnoses: n = 19 LBD (n = 17 Parkinson's disease [PD], n = 1 PD dementia, and n = 1 dementia with Lewy bodies), n = 31 APS (n = 28 MSA, n = 3 PSP), n = 3 non-neurodegenerative parkinsonism; n = 1 patient could not be diagnosed and was excluded. Receiver operating characteristic analyses for discriminating LBD vs. non-LBD revealed a larger area under the curve for FDG PET than for MIBG scintigraphy at statistical trend level for consensus rating (0.82 vs. 0.69, p = 0.06; significant for investigator #1: 0.83 vs. 0.69, p = 0.04). The analysis of PD vs. MSA showed a similar difference (0.82 vs. 0.69, p = 0.11; rater #1: 0.83 vs. 0.69, p = 0.07). Albeit the notable differences in diagnostic performance did not attain statistical significance, the authors consider this finding clinically relevant and suggest that FDG PET, which also allows for subgrouping of APS, should be preferred.
Introduction
We characterized dermal innervation in patients with fibromyalgia syndrome (FMS) as potential contribution to small fiber pathology.
Methods
Skin biopsies of the calf were collected (86 FMS patients, 35 healthy controls). Skin was immunoreacted with antibodies against protein gene product 9.5, calcitonine gene-related peptide, substance P, CD31, and neurofilament 200 for small fiber subtypes. We assessed two skin sections per patient; on each skin section, two dermal areas (150 x 700 mu m each) were investigated for dermal nerve fiber length (DNFL).
Results
In FMS patients we found reduced DNFL of fibers with vessel contact compared to healthy controls (p<0.05). There were no differences for the other nerve fiber subtypes.
Discussion
We found less dermal nerve fibers in contact with blood vessels in FMS patients than in controls. The pathophysiological relevance of this finding is unclear, but we suggest the possibility of a relationship with impaired thermal tolerance commonly reported by FMS patients.
Controlling posture, i.e., governing the ensemble of involuntary muscular activities that manage body equilibrium, represents a demanding function in which the cerebellum plays a key role. Postural activities are particularly important during gait initiation when passing from quiet standing to locomotion. Indeed, several studies used such motor task for evaluating pathological conditions, including cerebellar disorders. The linkage between cerebellum maturation and the development of postural control has received less attention. Therefore, we evaluated postural control during quiet standing and gait initiation in children affected by a slow progressive generalized cerebellar atrophy (SlowP) or non-progressive vermian hypoplasia (Joubert syndrome, NonP), compared to that of healthy children (H). Despite the similar clinical evaluation of motor impairments in NonP and SlowP, only SlowP showed a less stable quiet standing and a shorter and slower first step than H. Moreover, a descriptive analysis of lower limb and back muscle activities suggested a more severe timing disruption in SlowP. Such differences might stem from the extent of cerebellar damage. However, literature reports that during childhood, neural plasticity of intact brain areas could compensate for cerebellar agenesis. We thus proposed that the difference might stem from disease progression, which contrasts the consolidation of compensatory strategies.
The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3). Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in the full dataset (p = 3.17 × 10\(^{-4}\)). Importantly, logistic regression analyses conditioning on the main known MS-associated SNP at this locus, rs17066096, revealed that this association was independent from the primary association signal in the full case-control dataset. In silico analysis predicted both disruption of the alpha helix of the H-region of the SP and decreased hydrophobicity of this region, ultimately affecting the SP cleavage site. We tested the effect of the p.Leu16Pro variant on the secretion of IL-22BPi1, IL-22BPi2 and IL-22BPi3 and observed that the Pro16 risk allele significantly lowers secretion levels of each of the isoforms to around 50%–60% in comparison to the Leu16 reference allele. Thus, our study suggests that genetically coded decreased levels of IL-22BP isoforms are associated with augmented risk for MS.
Parkinson Patienten sind im Gegensatz zu gesunden Probanden in der kognitiven Verarbeitung zeitlicher Parameter, im Sinne einer Diskriminierungsfähigkeit für zeitliche Fehler innerhalb der Musikwahrnehmung beeinträchtigt. Dies betrifft lediglich die Zeiterkennung in höheren Intervallbereichen (> 600ms) und ist am ehesten durch Fluktuationen der Aufmerksamkeit, des Gedächtnisses, aber auch im Vergleich zu anderen Studien durch methodische Ansätze zu erklären. Durch die Koppelung des Audiostimulus an klare Rhythmusstrukturen weist diese Studie jedoch darauf hin, dass Überschneidungen zu anderen neuronalen Netzwerken existieren, die zur Kompensationsstrategie rekrutiert und nutzbar gemacht werden können. Dazu gehören etwa die Verarbeitung zeitlicher (Cerebellum) und musikperzeptiver Leistungen, wie etwa die Verarbeitung musikalischer Syntax (BA 6, 22, 44). Etwaige Wahrnehmungsdefizite können durch Mechanismen musiksyntaktischer Verarbeitung kompensiert werden, da zeitliche und syntaktische Strukturen in der Musik auf ihre Kongruenz hin abgeglichen und somit multineuronal mediiert werden (Paradigma der Zeit-Syntax-Kongruenz in der Musikwahrnehmung). Weiterhin sind vermutlich top-down-bottom-up-Prozesse als multimodale Interaktionen an diesem Kompensationsmechanismus beteiligt. Außerdem ist festzuhalten, dass das Krankheitsstadium nicht zwangsläufig mit einem stärkeren Wahrnehmungsdefizit für zeitliche Strukturen einhergehen muss, obwohl – wenn auch noch tolerabel – mit Progression der Erkrankung dieses Kompensationsmodell über Prinzipien der Gestaltwahrnehmung zusammenbricht und es hier zu schlechteren perzeptiven Leistungen kommen kann.
Die Ergebnisse der OFF-Testungen und jener unter DBS-Therapie lassen weiterhin aufgrund der kleinen Stichprobe keine klare Aussage zu und machen weitere Untersuchungen notwendig. Das physiologische Alter korreliert außerdem mit der sensorischen Leistung, die allerdings starken, individuellen Unterschieden ausgesetzt ist und von multifaktoriellen Voraussetzungen abhängt. Auch zeigt die Studie, dass Menschen mit einem hohen Musikverständnis und einer musikalischen Ausbildung ein feineres Diskriminierungsvermögen in der zeitlichen Verarbeitung besitzen, welches v.a. im zeitlich niedrigen Intervallbereich (< 500ms) evident wird.
Ischemic stroke caused by thromboembolic occlusion of large cerebral arteries, such as the internal carotid (ICA) and/or the middle cerebral artery (MCA), is treated by mechanical thrombectomy (MT). MT allows salvage of the vessel-occluding thrombemboli, which most frequently originate from the left atrium or the left ventricle of the heart or from sites of plaque rupture within large arteries above the heart. Clot composition may influence the efficacy of (intravenous) thrombolysis and MT, respectively. We analyzed 37 human thrombemboli obtained from acute ischemic stroke patients during MT with special emphasis on histological staining of neutrophils and neutrophil extracellular traps (NETs). We found neutrophils as the main cellular component of cerebral thrombemboli but encountered considerable morphological heterogeneity. Neutrophils accumulated in the border region of fibrin-rich structures indicating possible interaction of neutrophils with distinct structural thrombembolus components. Web-like NETs were found in 35 of 37 thrombemboli in varying amounts. NETs were almost exclusively found within fibrin-rich areas. Importantly, stroke etiology, age and present oral anticoagulation was associated with morphological patterns and the amount of neutrophils. Correlation of histological data and imaging data revealed that relative Hounsfield units of cerebral thrombemboli positively correlated with the amount of red blood cells. In summary, our results demonstrate that neutrophils and NETs are substantial constituents of cerebral thrombemboli and contribute to their structural complexity.
Die Small Fiber Neuropathie (SFN) bildet eine Untergruppe der sensiblen Neuropathien, bei der die Aδ- und C-Fasern betroffen sind. Die Patienten berichten v.a. von brennenden Schmerzen und Dysästhesien, seltener auch von autonomen Funktionsstörungen. Bei fehlendem Goldstandard und normalen Nervenleitungsstudien ist die Diagnostik erschwert, da selbst nach Spezialuntersuchungen wie Hautstanzbiopsie und quantitativer sensorischer Testung (QST) viele Patienten trotz typischer Anamnese der Diagnosestellung entgehen. Wir rekrutierten 55 Patienten und 31 gesunde Kontrollen. Nach neurologischer Untersuchung und Ausschluss einer Polyneuropathie mittels Elektroneurographie wurden bei allen Studienteilnehmern Hautstanzbiopsien am Ober- und Unterschenkel zur Ermittlung der intraepidermalen Nervenfaserdichte (IENFD) entnommen sowie eine QST zur Funktionsprüfung der kleinen Nervenfasern durchgeführt. Die Studienteilnehmer wurden zudem mit cornealer confocaler Mikroskopie (CCM) und der Ableitung Schmerz-assoziierter evozierter Potentiale (PREP) untersucht. Zur autonomen Testung erfolgte die Messung der Schweißproduktion mittels quantitativem sudomotorischem Axonreflextest (QSART). Die neurologische Untersuchung zeigte in 55% der Patienten Hinweise auf eine Kleinfaserpathologie. Die distale IENFD war bei 62% der Patienten reduziert, die QST bei 22% der Patienten auffällig. Die PREP Latenzen waren in der Patientengruppe länger als bei den Kontrollen, die Amplituden niedriger. Bei der cornealen Innervation zeigte sich eine Reduktion der Nervenfaserdichte, Nervenfaserlänge und Nervenastdichte. Die in QSART gemessenen Parameter zeigten sich zu 86% unauffällig. Während nach klinischer Untersuchung, Hautbiopsie und QST in 53% der Fälle in 2 von 3 Untersuchungen eine Pathologie der kleinen Fasern festgestellt werden konnte, stieg die Rate bei zusätzlicher Anwendung von PREP und CCM auf 80% (ohne Berücksichtigung von QST). Zusammenfassend sollten die klinische Untersuchung und die Hautstanzbiopsie bei allen Patienten mit Verdacht auf SFN erfolgen. PREP und CCM sind unter den verfügbaren zusätzlichen Untersuchungen diagnostisch am wertvollsten. Wichtig ist allerdings, dass bei fehlendem Goldstandard eine SFN auch bei unauffälligen Tests nicht ausgeschlossen werden kann. Zusätzlich können die Mikroneurographie und die genetische Analyse wertvolle Hinweise auf eine Kleinfaserfunktionsstörung und deren Pathophysiologie geben.
Background: Multiple sclerosis (MS) may cause variable functional impairment. The discrepancy between functional impairment and brain imaging findings in patients with MS (PwMS) might be attributed to differential adaptive and consolidation capacities. Modulating those abilities could contribute to a favorable clinical course of the disease.
Objectives: We examined the effect of cerebellar transcranial direct current stimulation (c-tDCS) on locomotor adaptation and consolidation in PwMS using a split-belt treadmill (SBT) paradigm.
Methods: 40 PwMS and 30 matched healthy controls performed a locomotor adaptation task on a SBT. First, we assessed locomotor adaptation in PwMS. In a second investigation, this training was followed by cerebellar anodal tDCS applied immediately after the task ipsilateral to the fast leg (T0). The SBT paradigm was repeated 24 h (T1) and 78 h (T2) post-stimulation to evaluate consolidation.
Results: The gait dynamics and adaptation on the SBT were comparable between PwMS and controls. We found no effects of offline cerebellar anodal tDCS on locomotor adaptation and consolidation. Participants who received the active stimulation showed the same retention index than sham-stimulated subjects at T1 (p = 0.33) and T2 (p = 0.46).
Conclusion: Locomotor adaptation is preserved in people with mild-to-moderate MS. However, cerebellar anodal tDCS applied immediately post-training does not further enhance this ability. Future studies should define the neurobiological substrates of maintained plasticity in PwMS and how these substrates can be manipulated to improve compensation. Systematic assessments of methodological variables for cerebellar tDCS are urgently needed to increase the consistency and replicability of the results across experiments in various settings.
Background
Patients with acute leukaemia have a high incidence of fungal infections. This has primarily been shown in acute myeloid leukaemia and is different for acute lymphoblastic leukaemia. Until now no benefit of mould active prophylaxis has been demonstrated in the latter population.
Methods
In this retrospective single‐centre study, we analysed the incidence, clinical relevance, and outcome of invasive fungal diseases (IFD) as well as the impact of antifungal prophylaxis for the first 100 days following the primary diagnosis of acute lymphoblastic leukaemia.
Results
In 58 patients a high rate of proven, probable, and possible fungal infections could be demonstrated with a 3.4%, 8.6%, and 17.2% likelihood, respectively. The incidence might be even higher, as nearly 40% of all patients had no prolonged neutropenia for more than 10 days, excluding those from the European Organization of Research and Treatment of cancer and the Mycoses Study Group criteria for probable invasive fungal disease. The diagnosed fungal diseases had an impact on the duration of hospitalisation, which was 13 days longer for patients with proven/probable IFD compared to patients with no signs of fungal infection. Use of antifungal prophylaxis did not significantly affect the risk of fungal infection.
Conclusion
Patients with acute lymphoblastic leukaemia are at high risk of acquiring an invasive fungal disease. Appropriate criteria to define fungal infections, especially in this population, and strategies to reduce the risk of infection, including antifungal prophylaxis, need to be further evaluated.
Background and Objective
This updated systematic review evaluated the efficacy, tolerability and safety of opioids compared to placebo in non‐malignant chronic low back pain.
Databases and Data Treatment
Clinicaltrials.gov, CENTRAL, MEDLINE and PsycINFO were searched from October 2013 to May 2019. Randomized controlled trials comparing opioids with placebo and at least 4 weeks of double‐blinded duration were analysed. Primary outcomes were pain relief of 50% or greater, disability, tolerability and safety. Effects were summarized by a random effects model using risk differences or standardized mean differences. We added nine new studies with 2,980 participants for a total of 21 studies with 7,650 participants. Study duration ranged between 4 and 15 weeks. Studies with a parallel and cross‐over design: Based on very low to low‐quality evidence, opioids provided no clinically relevant pain relief of 50% or greater, but a clinically relevant reduction of disability compared to placebo. Enriched enrolment randomized withdrawal (EERW) design: Based on very low to low‐quality evidence, opioids provided a clinically relevant pain relief of 50% or greater, but not a clinically relevant reduction of disability compared to placebo. There was no clinically relevant harm with regard to serious adverse events by opioids compared to placebo in studies with parallel/cross‐over and EERW design. There was a relevant harm with regard to drop out rates due to adverse events in studies with parallel/cross‐over, but not in studies with EERW design.
Conclusions
Opioids may provide a safe and clinically relevant pain relief for 4–15 weeks in highly selected patients.
Significance
Within the context of randomized controlled trials of 4–15 weeks, opioids provided a clinically relevant pain relief of 30% or greater and a clinically relevant reduction of disability compared to placebo in non‐malignant chronic low back pain. Number needed to treat for an additional drop out due to side effects was 11 (95% confidence interval: 6–33). Assessment of abuse and addiction was incomplete. The frequency of serious adverse events including deaths did not differ from placebo.
In our study, we aimed at investigating corneal langerhans cells (LC) in patients with fibromyalgia syndrome (FMS) and small fiber neuropathy (SFN) as potential contributors to corneal small fiber pathology. We enrolled women with FMS (n = 134) and SFN (n = 41) who underwent neurological examination, neurophysiology, prostaglandin analysis in tear fluid, and corneal confocal microscopy (CCM). Data were compared with those of 60 age‐matched female controls. After screening for dry eye disease, corneal LC were counted and sub‐classified as dendritic (dLC) and non‐dendritic (ndLC) cells with or without nerve fiber association. We further analyzed corneal nerve fiber density (CNFD), length (CNFL), and branch density (CNBD). Neurological examination indicated deficits of small fiber function in patients with SFN. Nerve conduction studies were normal in all participants. Dry eye disease was more prevalent in FMS (17%) and SFN (28%) patients than in controls (5%). Tear fluid prostaglandin levels did not differ between FMS patients and controls. While corneal LC density in FMS and SFN patients was not different from controls, there were fewer dLC in association with nerve fibers in FMS and SFN patients than in controls (P < .01 each). Compared to controls, CNFL was lower in FMS and SFN patients (P < .05 each), CNFD was lower only in FMS patients (P < .05), and CNBD was lower only in SFN patients (P < .001). There was no difference in any CCM parameter between patients with and without dry eyes. Our data indicate changes in corneal innervation and LC distribution in FMS and SFN, potentially based on altered LC signaling.
Comprehensive investigation in motor neuron disease is vital not to miss a treatable differential diagnosis. Neuroborreliosis should be considered during an ALS work‐up. However, false‐positive CSF results do occur, and thus, results should be interpreted carefully in context of all clinical test results.
Lewy bodies and Lewy neurites are neuropathological hallmarks of Parkinson’s disease (PD). These depositions in the brain mostly consist of aggregated α-synuclein (α-syn) phosphorylated at Ser129. A number of studies reported detection of phosphorylated α-syn (p-α-syn) in the dermal nerve fibers in Parkinson’s disease. The objective of this study was to investigate whether pathological α-syn accumulations detected in the skin represent aggregated protein. A number of methods aimed at detecting α-syn oligomers and aggregates were first tested and optimized on the brain samples in PD and normal control. These methods included proximity ligation assay (PLA), PET-blot, immunohistochemical (IHC) stains with α-syn aggregate (5G4) or oligomer specific (ASyO5) antibodies and a stain against native α-syn (syn211) after proteinase K (PK) digestion. Subsequently, the most specific methods (stains with 5G4, ASyO5 and syn211 after PK digestion) were studied in two separate patient and control cohorts. Anti-p-α-syn stain was performed in parallel.
Single sections from at least 2 biopsy sites from 44 patients and 22 controls (cohort 1) as well as serial sections of 4 biopsy sites from 27 patients and 5 controls (cohort 2) were systematically studied for presence of aggregated and oligomeric α-syn. In total, 5G4 positive deposits were found in 24% (cohort 1) and 37% (cohort 2), ASyO5 positive lesions in 17,7% (cohort 1) and 33% (cohort 2), syn211 positive lesions after PK digestion in 38,7% (cohort 1) and 48% (cohort 2) of cases. There was a major overlap among positivity for a particular staining on the patient level and in most cases, the same nerve fiber was found to be positive for all 4 markers in neighboring sections. Among the skin biopsies which contained p-α-syn accumulation, 59% were also PK resistant, 41% were 5G4 positive and 45% were ASyO5 positive. The samples belonging to normal controls did not show any positive signal in either of the newly established stainings or in the anti-p-α-syn staining.
Using 3 distinct IHC methods, α-syn oligomers and aggregates were detectable in the majority of p-α-syn positive skin biopsies. This finding supports the hypothesis that α-syn aggregation occurs in the peripheral (i.e. dermal) nerves and can be specifically detected using skin biopsy.
Die aneurysmatische SAB ist trotz etablierter Therapieverfahren (Coiling und Clipping) weiterhin ein Krankheitsbild mit hoher Mortalität. In unserer Arbeit haben wir retrospektiv die Patientenakten der Patienten, die mit der Diagnose aneurysmatische SAB am Universitätsklinikum Würzburg zwischen dem 01.01.1999 und dem 31.12.2009 aufgenommen wurden, ausgewertet. Es konnte dargestellt werden das als Hauptrisikofaktoren für ein schlechtes Therapieergebnis ein schlechter Aufnahmestatus des Patienten und das Auftreten von Komplikationen im Verlauf verantwortlich sind.
In den Jahren von 2006 bis 2016 sind am Universitätsklinikum Würzburg insgesamt 26 Patienten mit der Diagnose einer Autoimmunen Enzephalitis behandelt worden. Diese Arbeit zeigt ihre Krankheitsverläufe, Outcome, die gefundenen Antikörper und die Therapien der jeweiligen Patienten. Im zweiten Schritt wurden die Daten mit den in der Literatur bereits beschrieben Fällen verglichen, um Gemeinsamkeiten, aber auch Unterschiede aufzeigen zu können.
Objective
Bridging the gap between experimental stroke and patients by ischemic blood probing during the hyperacute stage of vascular occlusion is crucial to assess the role of inflammation in human stroke and for the development of adjunct treatments beyond recanalization.
Methods
We prospectively observed 151 consecutive ischemic stroke patients with embolic large vessel occlusion of the anterior circulation who underwent mechanical thrombectomy. In all these patients, we attempted microcatheter aspiration of 3 different arterial blood samples: (1) within the core of the occluded vascular compartment and controlled by (2) carotid and (3) femoral samples obtained under physiological flow conditions. Subsequent laboratory analyses comprised leukocyte counting and differentiation, platelet counting, and the quantification of 13 proinflammatory human chemokines/cytokines.
Results
Forty patients meeting all clinical, imaging, interventional, and laboratory inclusion criteria could be analyzed, showing that the total number of leukocytes significantly increased under the occlusion condition. This increase was predominantly driven by neutrophils. Significant increases were also apparent for lymphocytes and monocytes, accompanied by locally elevated plasma levels of the T‐cell chemoattractant CXCL‐11. Finally, we found evidence that short‐term clinical outcome (National Institute of Health Stroke Scale at 72 hours) was negatively associated with neutrophil accumulation.
Interpretation
We provide the first direct human evidence that neutrophils, lymphocytes, and monocytes, accompanied by specific chemokine upregulation, accumulate in the ischemic vasculature during hyperacute stroke and may affect outcome. These findings strongly support experimental evidence that immune cells contribute to acute ischemic brain damage and indicate that ischemic inflammation initiates already during vascular occlusion. Ann Neurol 2020;87:466–479
Fatigue als ein „überwältigendes Gefühl von Müdigkeit, Energielosigkeit und Erschöpfung” stellt bei Patienten mit MS ein häufig auftretendes und oft im Alltag beeinträchtigendes Symptom dar, das sowohl mit körperlichen als auch mit kognitiven Erschöpfungssymptomen einhergeht. Die objektive Erfassung des Schweregrades der Fatigue beim einzelnen Patienten stellt ein Problem dar, da bisher keine objektiven Messverfahren zur Erfassung der Fatigue existieren. Im klinischen Alltag kommen meist Fragebögen zum Einsatz, die das Ausmaß der subjektiven Beeinträchtigung durch Fatigue im Alltag quantifizieren sollen.
Ziel dieser Arbeit war es, zu untersuchen, inwieweit bestimmte im klinischen Alltag erhobene Parameter Rückschlüsse auf die subjektive Fatigue bei Patienten mit MS erlauben, auch im Hinblick darauf, ob sich einzelne Parameter besonders zur Einschätzung der körperlichen bzw. kognitiven Fatigue eignen. Zudem sollte untersucht werden, ob die untersuchten klinischen Parameter bei bestimmten Patientengruppen besser als bei anderen Rückschlüsse auf die subjektive Fatigue erlauben. Erfasst wurde die subjektive Fatigue durch das Würzburger Erschöpfungsinventar bei Multipler Sklerose (WEIMuS), einer Serie von Fragen, die zwischen körperlicher und kognitiver Fatigue unterscheiden.
Dazu wurden Korrelationsanalysen zwischen der WEIMuS-Gesamtskala bzw. deren Subskalen für körperliche und kognitive Fatigue und EDSS-Wert, MSFC Z-Score einschließlich dessen Subscores und der Zeit des 50-Meter-Gehversuchs durchgeführt. Bezüglich der körperlichen Fatigue ergaben sich zwischen der WEIMuS-Subskala für körperliche Fatigue und dem EDSS sowie der Zeit des 50-Meter-Gehversuchs im Vergleich die stärksten, absolut gesehen als mittelstark zu wertende, Korrelationen. Bezüglich der kognitiven Fatigue ergab sich die stärkste Korrelation zwischen der WEIMuS-Subskala für kognitive Fatigue und dem PASAT3, die allerdings trotzdem als gering zu werten ist. Mit EDSS und 50-Meter-Gehversuch scheinen also zwei objektive klinische Parameter zu existieren, die in einem gewissen Maß auf die subjektive Fatigue rückschließen lassen. Ziel weiterer Untersuchungen wird es sein müssen, einen geeigneten klinischen Parameter zu finden, der bessere Rückschlüsse auf die subjektive kognitive Fatigue erlaubt als der PASAT3.
Zwischen der WEIMuS-Gesamtskala bzw. deren Subskalen für körperliche und kognitive Fatigue und Alter, Geschlecht und Erkrankungsdauer fanden sich bestenfalls geringe Korrelationen, weshalb diese Parameter ungeeignet erscheinen, Aussagen über die subjektive Fatigue zu machen.
Durch die Einteilung der Patienten nach Alter und Geschlecht konnte untersucht werden, inwieweit diese Parameter Einfluss auf die untersuchten Zusammenhänge zwischen klinischen Parametern und subjektiver Fatigue haben. Die Korrelationen zwischen den WEIMuS-Subskalen für körperliche und kognitive Fatigue mit den untersuchten klinischen Parametern waren für junge Patienten überwiegend stärker als für ältere Patienten, insbesondere ältere Männer. Somit scheinen die untersuchten klinischen Parameter bei jüngeren Patienten besser geeignet, Aussagen über die subjektive Fatigue zu machen als bei älteren.
Insgesamt ist festzuhalten, dass EDSS und 50-Meter-Gehversuch insbesondere bei jungen Patienten zu einer besseren objektiven Beurteilbarkeit vor allem der körperlichen Fatigue im klinischen Alltag beitragen können.
Mesenchymal stem cell (MSC)-secreted factors have been shown to significantly promote oligodendrogenesis from cultured primary adult neural stem cells (aNSCs) and oligodendroglial precursor cells (OPCs). Revealing underlying mechanisms of how aNSCs can be fostered to differentiate into a specific cell lineage could provide important insights for the establishment of novel neuroregenerative treatment approaches aiming at myelin repair. However, the nature of MSC-derived differentiation and maturation factors acting on the oligodendroglial lineage has not been identified thus far. In addition to missing information on active ingredients, the degree to which MSC-dependent lineage instruction is functional in vivo also remains to be established. We here demonstrate that MSC-derived factors can indeed stimulate oligodendrogenesis and myelin sheath generation of aNSCs transplanted into different rodent central nervous system (CNS) regions, and furthermore, we provide insights into the underlying mechanism on the basis of a comparative mass spectrometry secretome analysis. We identified a number of secreted proteins known to act on oligodendroglia lineage differentiation. Among them, the tissue inhibitor of metalloproteinase type 1 (TIMP-1) was revealed to be an active component of the MSC-conditioned medium, thus validating our chosen secretome approach.
LSVT-BIG therapy in Parkinson's disease: physiological evidence for proprioceptive recalibration
(2020)
Background
There is growing evidence for proprioceptive dysfunction in patients with Parkinson's disease (PD). The Lee Silvermann Voice Treatment-BIG therapy (LSVT-BIG), a special training program aiming at an increase of movement amplitudes in persons with PD (PwPD), has shown to be effective on motor symptoms. LSVT-BIG is conceptionally based on improving bradykinesia, in particular the decrement of repetitive movements, by proprioceptive recalibration.
Objective
To assess proprioceptive impairment in PwPD as compared to matched controls and to probe potential recalibration effects of the LSVT-BIG therapy on proprioception.
Methods
Proprioceptive performance and fine motor skills were assessed in 30 PwPD and 15 matched controls. Measurements with significant impairment in PwPD were chosen as outcome parameters for a standardized 4 weeks amplitude-based training intervention (LSVT-BIG) in 11 PwPD. Proprioceptive performance served as primary outcome measure. Secondary outcome measures included the motor part of the MDS-UPDRS, the nine-hole-peg test, and a questionnaire on quality of life. Post-interventional assessments were conducted at weeks 4 and 8. Results Compared to the control group, PwPD showed significantly larger pointing errors. After 4 weeks of LSVT-BIG therapy and even more so after an additional 4 weeks of continued training, proprioceptive performance improved significantly. In addition, quality of life improved as indicated by a questionnaire.
Conclusion
LSVT-BIG training may achieve a recalibration of proprioceptive processing in PwPD. Our data indicates a probable physiological mechanism of a symptom-specific, amplitude-based behavioral intervention in PwPD.
Background and Objective
This updated systematic review evaluated the efficacy, tolerability and safety of opioids compared to placebo in chronic non‐cancer neuropathic pain.
Databases and Data Treatment
Clinicaltrials.gov, CENTRAL, PubMed and PsycINFO were searched from October 2013 to June 2019. Randomized controlled trials comparing opioids with placebo and at least 4 weeks double‐blinded duration were analysed. Primary outcomes were pain relief of 50% or greater, disability, tolerability and safety. Effects were summarized by a random effects model using risk differences (RD) or standardized mean differences (SMD). We added four new studies with 662 participants for a total of 16 included studies with 2,199 participants. Study duration ranged between 4 and 12 weeks. Studies with a parallel and cross‐over design: Based on low to moderate quality evidence, opioids (buprenorphine, hydromorphone, morphine, oxycodone, tramadol) provided a clinically relevant pain relief of 50% or greater and reduction of disability compared to placebo. There was no clinically relevant harm with regards to the drop out rate due to adverse and serious adverse events by opioids compared to placebo. Enriched enrolment randomized withdrawal design: Based on low to moderate quality evidence, tapentadol provided a clinically relevant pain relief of 50% or greater and reduction of disability compared to placebo in diabetic polyneuropathy. There was no clinically relevant harm with regards to the drop out rate due to adverse and serious adverse events by tapentadol compared to placebo.
Conclusions
Some opioids provided a short‐term substantial pain relief in highly selected patients in some neuropathic pain syndromes.
Significance
Some opioids (buprenorphine, morphine, oxycodone, tramadol, tapentadol) provide substantial pain relief compared to placebo in postherpetic neuralgia and peripheral neuropathies of different aetiologies for 4–12 weeks. There is insufficient evidence to support or refute the suggestion that these drugs are effective in other neuropathic pain conditions. The safety of opioids with regards to abuse and deaths in the studies analysed cannot be extrapolated to routine clinical care.